1.2 Safety considerations and the limits of the GLP-1 analogy The success of GLP-1 receptor agonists should not obscure legitimate safety considerations associated with chronic peptide therapy
9.1 Criteria suggesting failed pharmacology rather than failed biology Several characteristics consistently indicate that a peptide system may have been abandoned prematurely due to pharmacologic or methodological limitations rather than biological inadequacy
Symptoms requiring routine medical review: Bloating that persists beyond 46 weeks despite dietary modifications and adequate dose titration Symptoms that significantly impact quality of life or ability to maintain adequate nutrition New or worsening heartburn or regurgitation, which may indicate gastro-oesophageal reflux disease (GORD) Changes in bowel habit such as persistent diarrhoea or constipation Concerns about medication adherence due to gastrointestinal side effects Your healthcare professional may recommend investigations to exclude other causes of bloating, particularly if symptoms are atypical or severe
Minskar distraktioner St, fet och ultraprocessad mat kan trigga igng belningssystemen i vra hjrnor, vilket gr att vi vill ha mer ven nr vi inte r hungriga, GLP-1-lkemedel kan pverka hjrnans belningscentra och minska matsuget
Never share injection pens or devices with others, even if the needle has been changed, as this poses serious infection risks
Schedule your consultation today and discover a supportive, science-backed approach to weight management
